在一项为期14天的单药治疗研究中，HBeAg阳性慢性乙型肝炎患

StephenW

The Second-Generation Hepatitis B Virus (HBV) Core Inhibitor (CI) ABI-H2158is Associated with Potent Antiviral Activity in a 14-Day Monotherapy Studyin HBeAg-positive Patients with Chronic Hepatitis B (CHB)                                                                         AASLD 2019 Nov 8-12 Boston Reported by Jules Levin Man-Fung Yuen1, Kosh Agarwal2, Ed Gane3, Tuan T. Nguyen4, Tarek I. Hassanein5, Dong Joon Kim6, Katia Alves7, Hany Zayed7, Dongmei Qiang7, Eric Ruby7, Marc Evanchik7, Qi Huang7, Steven J. Knox7, and Richard Colonno7 on behalf of the ABI-H2158 Study Team 1University of Hong Kong, Hong Kong; 2King's College Hospital Foundation Trust, London, United Kingdom; 3Auckland Clinical Studies Limited, Auckland, New Zealand; 4T. Nguyen Research and Education, San Diego, CA;5Southern California Research Center, Coronado, CA; 6Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea; 7Assembly Biosciences, Inc., South San Francisco, CA